title: [Efficacy of 5-FU hepatic arterial infusion with l-leucovorin for patients with unresectable colorectal liver metastasis].
abstract: We investigated the efficacy of 5-FU hepatic artery infusion (HAI)for patients with unresectable colorectal liver metastasis. Fifteen patients who received HAI between June 2004 and December 2006 were studied. HAI was attempted as first-line chemotherapy in seven patients(Group A)and as second-line or more in eight(Group B). The response rate, time to progression, survival and toxicity were compared with those of 39 patients treated with systemic chemotherapy(18 as first-line: Group C, 21 as second-line or more: Group D). Response rate was 85.7%, 35.7%, 50.0%, and 4.8% in Groups A, B, C, and D, respectively. Time to progression was 12.5 months, 4.7 months, 5.8 months, and 2.3 months, in Groups A, B, C, and D, respectively, and significantly longer in Group A compared with Group C, as well as in Group B compared with Group D. Median survival was 15.4 months, 9.1 months, 11.3 months, and 8.0 months in Groups A, B, C, and D, respectively, and significantly longer in Group B compared with Group D. Grade 3 or 4 non-hematological toxicity was not observed in Group A and B. HAI was effective for the control of unresectable colorectal liver metastasis and improved survival as second-line chemotherapy or more.
authors.affiliation: Dept. of Surgery, Rinku General Medical Center, Izumisano Municipal Hospital.
authors.forename: Tsunekazu
authors.initials: T
authors.lastname: Mizushima
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Mizuno
authors.forename: Takashi
authors.initials: T
authors.lastname: Sugiura
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Ito
authors.forename: Yuko
authors.initials: Y
authors.lastname: Udatsu
authors.forename: Mika
authors.initials: M
authors.lastname: Okazawa
authors.forename: Keijiro
authors.initials: K
authors.lastname: Sugimura
authors.forename: Akira
authors.initials: A
authors.lastname: Tomokuni
authors.forename: Hidenori
authors.initials: H
authors.lastname: Kusumoto
authors.forename: Tomo
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Tomoya
authors.initials: T
authors.lastname: Kishimoto
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwase
authors.forename: Masaaki
authors.initials: M
authors.lastname: Izukura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D002955:Leucovorin; D005472:Fluorouracil